<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114330">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01937767</url>
  </required_header>
  <id_info>
    <org_study_id>CNS7056-010</org_study_id>
    <nct_id>NCT01937767</nct_id>
  </id_info>
  <brief_title>Remimazolam Phase II Cardiac Anesthesia Study</brief_title>
  <official_title>A Randomized, Single-blind Phase II Study Evaluating the Efficacy, Safety and Pharmacokinetics of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery, Including Follow-up Sedation in the PACU/ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paion UK Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aptiv Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Paion UK Ltd.</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II study in patients undergoing elective cardiac surgery will evaluate the
      efficacy, safety, and pharmacokinetics of remimazolam, compared with propofol and
      sevoflurane, during the induction and maintenance of general anesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of patients with successful anesthesia</measure>
    <time_frame>Between the start of study medication and the end of the surgical procedure (up to approx 12 hours)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>General Anesthesia</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction: Propofol, fentanyl, rocuronium. Maintenance: Sevoflurane, remifentanil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remimazolam 6 mg/kg/hr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction: Remimazolam 6 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remimazolam 12 mg/kg/hr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction: Remimazolam 12 mg/kg/hr, fentanyl, rocuronium. Maintenance: Remimazolam up to 2 mg/kg/hr titrated to effect, remifentanil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam</intervention_name>
    <arm_group_label>Remimazolam 6 mg/kg/hr</arm_group_label>
    <arm_group_label>Remimazolam 12 mg/kg/hr</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_label>Remimazolam 6 mg/kg/hr</arm_group_label>
    <arm_group_label>Remimazolam 12 mg/kg/hr</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_label>Remimazolam 6 mg/kg/hr</arm_group_label>
    <arm_group_label>Remimazolam 12 mg/kg/hr</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_label>Remimazolam 6 mg/kg/hr</arm_group_label>
    <arm_group_label>Remimazolam 12 mg/kg/hr</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  scheduled for major elective cardiac surgery.

          -  scheduled for mechanical ventilation via tracheal intubation.

        Exclusion Criteria:

          -  thoraco-abdominal replacement of the aorta or other procedure expected to be
             accompanied by a massive hemorrhage (at least 15% of the circulating blood volume).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Probst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Leipzig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzzentrum Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 11, 2014</lastchanged_date>
  <firstreceived_date>August 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
